Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;36(6):1277-1286.
doi: 10.3803/EnM.2021.1251. Epub 2021 Dec 16.

Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study

Affiliations

Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study

Eyun Song et al. Endocrinol Metab (Seoul). 2021 Dec.

Abstract

Background: The detrimental effects of excessive thyroid hormone on glucose metabolism have been widely investigated. However, the risk of diabetes in patients with long-standing hyperthyroidism, especially according to treatment modality, remains uncertain, with few longitudinal studies.

Methods: The risk of diabetes in patients with Graves' disease treated with antithyroid drugs (ATDs) for longer than the conventional duration (≥2 years) was compared with that in age-and sex-matched controls. The risk was further compared according to subsequent treatment modalities after a 24-month course of ATD: continuation of ATD (ATD group) vs. radioactive iodine ablation (RIA) group.

Results: A total of 4,593 patients were included. Diabetes was diagnosed in 751 (16.3%) patients over a follow-up of 7.3 years. The hazard ratio (HR) for diabetes, after adjusting for various known risk factors, was 1.18 (95% confidence interval [CI], 1.10 to 1.28) in patients with hyperthyroidism. Among the treatment modality groups, the RIA group (n=102) had a higher risk of diabetes than the ATD group (n=4,491) with HR of 1.56 (95% CI, 1.01 to 2.42). Further, the risk of diabetes increased with an increase in the ATD treatment duration (P for trend=0.019).

Conclusion: The risk of diabetes was significantly higher in patients with long-standing Graves' disease than in the general population, especially in patients who underwent RIA and prolonged ATD treatment. Special attention to hyperglycemia during follow-up along with effective control of hyperthyroidism may be necessary to reduce the risk of diabetes in these patients.

Keywords: Antithyroid agents; Diabetes mellitus; Graves disease; Hyperthyroidism; Radioiodine ablation.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Flowchart of the study. DM, diabetes mellitus; ATD, antithyroid drug; RIA, radioactive iodine ablation.
Fig. 2
Fig. 2
Kaplan–Meier curves for cumulative incidence of new-onset diabetes (A) in total long-standing Graves’ patients and (B) among the treatment modality groups compared to the controls. ATD, antithyroid drug; RIA, radioactive iodine ablation.
Fig. 3
Fig. 3
Subgroup analysis comparing the hazard ratios (HRs) for developing diabetes between long-lasting graves’ patients and matched control group. The HRs were determined by conducting a multivariate Cox proportional hazards regression analysis adjusting for age, sex, body mass index, smoking status, alcohol consumption, regular exercise, hypertension (HTN), dyslipidemia, systolic blood pressure, low-density lipoprotein, and fasting glucose. BMI, body mass index; CI, confidence interval.

Comment in

References

    1. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388:906–918. - PMC - PubMed
    1. Cooper DS. Hyperthyroidism. Lancet. 2003;362:459–68. - PubMed
    1. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–58. - PubMed
    1. Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Antithyroid drugs-the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26:1144–5. - PubMed
    1. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;2010:CD003420. - PMC - PubMed

Publication types

MeSH terms

Substances